1404-04-2

• 常用中文名：新霉素B
• 常用英文名：Neomycin
• CAS号：1404-04-2
• 分子式：C₂₃H₅₂N₆O₂₅S₃
• 分子量：614.644
• 相关类别： 原料药 抗生素类药物 氨基糖苷类药
• 发布时间：2018-08-30 22:03:20
• 更新时间：2024-01-02 13:37:42
• Neomycin是一种氨基糖苷类抗生素。Neomycin可用于研究外部或内部细菌感染,主要以硫酸盐形式用于兽医学。

名称

• 中文名: 新霉素
• 英文名: neomycin sulfate
• 中文别名: 新霉素B
• 英文别名: Actilin; neomin; Neosulf; neomcin; nivemycin; Myacine; EINECS 215-773-1; NEOMIX; Endomixin; Bykomycin; Neobiosamine B; Framygen; Jernadex; Antibiotique EF 185; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-b-L-idopyranosyl)-b-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-a-D-glucopyranoside; myacyne; Enterfram; α-D-Glucopyranoside, (1R,2R,3S,4R,6S)-4,6-diamino-2-[[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]oxy]-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-; Bycomycin; neolate; Neomyacin; Neobrettin; Framycetin; Biosol; Tuttomycin; a-D-glucopyranoside, (1R,2R,3S,4R,6S)-4,6-diamino-2-[[3-O-(2,6-diamino-2,6-dideoxy-b-L-idopyranosyl)-b-D-ribofuranosyl]oxy]-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-; Fraquinol; Neomycin; (1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-α-D-glucopyranoside; neomas

物化性质

• 密度: 1.6±0.1 g/cm3
• 沸点: 927.1±65.0 °C at 760 mmHg
• 分子式: C₂₃H₅₂N₆O₂₅S₃
• 分子量: 614.644
• 闪点: 514.5±34.3 °C
• 精确质量: 614.312256
• PSA: 602.05000
• LogP: -3.65
• 外观性状: powder
• 蒸汽压: 0.0±0.6 mmHg at 25°C
• 折射率: 1.675
• 储存条件: 2-8°C
• 水溶解性: H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8°C. Stable at 37°C for 5 days.
• 分子结构:

  1、摩尔折射率：无可用的

  2、摩尔体积（cm³/mol）：无可用的

  3、等张比容（90.2K）：无可用的

  4、表面张力（dyne/cm）：无可用的

  5、介电常数：无可用的

  6、极化率（10^-24cm³）：无可用的

  7、单一同位素质量：908.214421 Da

  8、标称质量：908 Da

  9、平均质量：908.8792 Da

• 计算化学:

  1.疏水参数计算参考值（XlogP）:-9

  2.氢键供体数量:13

  3.氢键受体数量:19

  4.可旋转化学键数量:9

  5.互变异构体数量:无

  6.拓扑分子极性表面积353

  7.重原子数量:42

  8.表面电荷:0

  9.复杂度:872

  10.同位素原子数量:0

  11.确定原子立构中心数量:19

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：白色或类白色粉末

  2. 密度（g/mL,25℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：57-58

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,3mmHg）：未确定

  7. 折射率(n20/D)：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（mmHg,20ºC）：未确定

  12. 饱和蒸气压（kPa,25ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：极易溶于水，极微溶于乙醇，不溶于乙醚、丙酮、氯仿

生物活性

• 描述: Neomycin是一种氨基糖苷类抗生素。Neomycin可用于研究外部或内部细菌感染,主要以硫酸盐形式用于兽医学。
• 相关类别:
  研究领域 >> 感染
• 参考文献:

  [1]. Liu Y, et al. Pharmacokinetics of neomycin sulfate after intravenous and oral administrations in swine. J Vet Pharmacol Ther. 2021 Sep;44(5):850-853.

毒性和生态

毒理学数据: 1、急性毒性：女人经口TDLo：220mg/kg/2D；人TDLo：57mg/kg；大鼠经口LD50：2750mg/kg；大鼠经皮下LD50：633mg/kg；小鼠经口LD50：2880mg/kg；小鼠经腹腔LD50：116mg/kg；小鼠经皮下LD50：275mg/kg；小鼠经静脉LD50：27600μg/kg； 2、其他多剂量毒性：大鼠经皮下TDLo：500mg/kg/5D-I； 3、 致突变性 大肠杆菌的DNA加和：20mg/L； 人淋巴细胞的细胞遗传学分析：80 mg/L/24H（Continuous）； 小鼠肠外的细胞遗传学分析：50 mg/kg； CHEMICAL IDENTIFICATION RTECS NUMBER : QP3850000 CHEMICAL NAME : Neomycin CAS REGISTRY NUMBER : 1404-04-2 LAST UPDATED : 199609 WISWESSER LINE NOTATION : T6OTJ CZ DQ EQ F1Z BO- CT5OTJ B1Q DQ EO- CL6TJ AZ BQ EZ DO- BT6OTJ CZ DQ EQ F1Z HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 220 mg/kg/2D TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - change in acuity Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human DOSE/DURATION : 57 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - changes in cochlear structure or function Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2750 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 633 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2880 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 116 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 275 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 27600 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 500 mg/kg/5D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) MUTATION DATA TEST SYSTEM : Rodent - mouse DOSE/DURATION : 50 mg/kg REFERENCE : CHRTBC Chromosomes Today. (George Allen & Unwin Ltd., 40 Museum St., London WC1A 1LU, UK) V.1- 1966- Volume(issue)/page/year: 4,277,1973 *** REVIEWS *** TOXICOLOGY REVIEW CPJOAC Canadian Pharmaceutical Journal. (Canadian Pharmaceutical Assoc., 101-1815 Alta Vista Dr., Ottawa, Ont., Canada) V.1- 1868- Volume(issue)/page/year: 108(3),88,1975 TOXICOLOGY REVIEW CLANA4 Clinical Anesthesia. (Philadelphia, PA 19103) V.1-11, 1963-76. Volume(issue)/page/year: 10(Pt 1),283,1973 TOXICOLOGY REVIEW MMWOAU Muenchener Medicinische Wochenschrift. (Munich, Fed. Rep. Ger.) V.33-115, 1886-1973. Volume(issue)/page/year: 115,1661,1973 TOXICOLOGY REVIEW AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3705 No. of Facilities: 567 (estimated) No. of Industries: 2 No. of Occupations: 11 No. of Employees: 19997 (estimated) No. of Female Employees: 16532 (estimated)

安全

• 危害码 (欧洲): Xn: Harmful;
• 风险声明 (欧洲): R42/43
• 安全声明 (欧洲): S22;S45;S36/S37
• WGK德国: 3
• RTECS号: QP4375000

制备

以链霉菌做菌种，经培养发酵得到发酵液，加过强酸型阳离子交换树脂之后，用氨水洗脱，然后将洗脱液经薄膜浓缩，硫酸中后经喷雾干燥制的。新霉素为多组分氨基抗生素。主要组分为新霉素B和C，含微量新霉素A。